Actively Recruiting
Phase 1b Trial Evaluating Pasritamig Combined with Other Treatments for Metastatic Prostate Cancer
Led by Janssen Research & Development, LLC · Updated on 2026-07-06
300
Participants Needed
15
Research Sites
38 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying pasritamig JNJ-78278343 combined with several other agents for men with metastatic prostate cancer, including metastatic castration-resistant prostate cancer mCRPC and metastatic hormone-sensitive prostate cancer mHSPC. The study aims to find the recommended phase 2 dose regimen of pasritamig with these combination treatments and to evaluate their safety. Participants receive pasritamig and one of several combination agents such as cetrelimab, cabazitaxel, docetaxel, apalutamide, enzalutamide, darolutamide, abiraterone acetate plus prednisone, lutetium Lu-177 vipivotide tetraxetan, or JNJ-101556143. Part 1 involves dose escalation of pasritamig with these agents to identify the recommended dose, and Part 2 involves dose expansion where participants receive pasritamig and the combination agents at the identified dose. During the study, researchers monitor participants for dose-limiting toxicities and adverse events for up to nearly three years. They assess outcomes including overall response rate, prostate-specific antigen response, radiographic progression-free survival, time to response, and duration of response. Participants are evaluated regularly with clinical and laboratory tests, and safety is carefully monitored throughout the trial.
CONDITIONS
Brief Title
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Research Team
S
Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
